Paragon Capital Management (Utah)’s Moderna MRNA Stock Holding History

Paragon Capital Management (Utah)’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,007	Closed	-$669K	–	81
2024 Q3	$669K	Buy	10,007 +4,937	+97%	+$453K	0.49%	58
2024 Q2	$602K	Buy	+5,070	New	+$642K	0.46%	57
2023 Q1	–	Sell	-7,228	Closed	-$1.3M	–	75
2022 Q4	$1.3M	Sell	7,228 -521	-7%	-$85.2K	1.21%	18
2022 Q3	$916K	Sell	7,749 -1,103	-12%	-$167K	0.9%	44
2022 Q2	$1.26M	Sell	8,852 -5,675	-39%	-$811K	1.28%	18
2022 Q1	$2.5M	Buy	14,527 +5,205	+56%	+$876K	2.32%	8
2021 Q4	$2.37M	Buy	+9,322	New	+$2.73M	2.02%	11

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Paragon Capital Management (Utah)'s MRNA Position: Q4 2024 in Review

Paragon Capital Management (Utah) sold out of Moderna (MRNA) in Q4 2024, closing a stake of 10,007 shares — an estimated $669K sold.

Paragon Capital Management (Utah) first reported a position in MRNA in Q4 2021 and held it in 7 quarters. The position peaked at $2.5M in Q1 2022. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

Paragon Capital Management (Utah) reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
Paragon Capital Management (Utah) sold 10,007 Moderna shares in Q4 2024, an estimated $669K.
Paragon Capital Management (Utah) first reported a position in Moderna in Q4 2021 and held it in 7 quarters.
Paragon Capital Management (Utah)'s Moderna position peaked at $2.5M in Q1 2022.
745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Paragon Capital Management (Utah)'s 13F filing for Q4 2024, filed 27 Jan 2025.